FDA-cleared profile

LungMaps

Siemens Healthineers AG · MRI · FDA-cleared (510(k))

Authorized purpose: LungMaps processes one or more 2D lung MRI time series to support radiologist interpretation of ventilation and perfusion maps; it is not the sole source for diagnosis.

Clinical role
Post-processing analysis
Images and patients
MRI · Chest/Lung
Key limitation
Keep in mind: Results when interpreted by a radiologist may assist in diagnosis; the results shall not be used as the only source for diagnosis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: LungMaps processes one or more 2D lung MRI time series to support radiologist interpretation of ventilation and perfusion maps; it is not the sole source for diagnosis.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Chest/Lung Input: One or more 2D MRI time series for lung analysis.
  • Who uses it?Intended users: Healthcare professionals.
  • What does the software produce?Output: Lung ventilation/perfusion maps and statistical evaluation.
  • What is its most important limitation?Key limitation: Results when interpreted by a radiologist may assist in diagnosis; the results shall not be used as the only source for diagnosis.

Clinical takeaway. Clinical role: LungMaps processes one or more 2D lung MRI time series to support radiologist interpretation of ventilation and perfusion maps; it is not the sole source for diagnosis.

Evidence takeaway. Evidence from the reviewed source record: Non-clinical testing used 342 test images; the average Dice score was 0.91, the average Hausdorff distance was 4.1 pixels (SD = 3.9), the average surface distance was 0.8 pixels (SD = 0.8), the average absolute volumetric difference was 2.5 (SD = 159.5), and the relative volumetric difference was 3.2 (SD = 21.4). The representative dataset included 0.55T, 1.5T, and 3T MRI systems and subjects aged 6 to 85 years; no clinical tests were conducted for the subject device.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
LungMaps processes one or more 2D lung MRI time series to support radiologist interpretation of ventilation and perfusion maps; it is not the sole source for diagnosis.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Post-processing analysis
  • Exact FDA submission
  • Checked 2026-09-05
Required input
One or more 2D MRI time series for lung analysis.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Lung ventilation/perfusion maps and statistical evaluation.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Patients aged 6 years and older.
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Healthcare professionals.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet states that the device is intended for healthcare professionals and does not establish a more specific user role.

Limitations
Results when interpreted by a radiologist may assist in diagnosis; the results shall not be used as the only source for diagnosis.
  • Exact FDA submission
  • Checked 2026-09-19

The exact intended-use statement provides the radiologist-interpretation and diagnosis boundary.

Evidence summary
Non-clinical testing used 342 test images; the average Dice score was 0.91, the average Hausdorff distance was 4.1 pixels (SD = 3.9), the average surface distance was 0.8 pixels (SD = 0.8), the average absolute volumetric difference was 2.5 (SD = 159.5), and the relative volumetric difference was 3.2 (SD = 21.4). The representative dataset included 0.55T, 1.5T, and 3T MRI systems and subjects aged 6 to 85 years; no clinical tests were conducted for the subject device.
  • Exact FDA submission
  • Checked 2026-09-19

The exact FDA summary reports the test-set size, segmentation metrics, field strengths, age range, and absence of clinical tests.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Non-clinical testing used 342 test images; the average Dice score was 0.91, the average Hausdorff distance was 4.1 pixels (SD = 3.9), the average surface distance was 0.8 pixels (SD = 0.8), the average absolute volumetric difference was 2.5 (SD = 159.5), and the relative volumetric difference was 3.2 (SD = 21.4). The representative dataset included 0.55T, 1.5T, and 3T MRI systems and subjects aged 6 to 85 years; no clinical tests were conducted for the subject device.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact FDA summary reports the test-set size, segmentation metrics, field strengths, age range, and absence of clinical tests.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

Segmentation Dice is not a diagnostic sensitivity measure.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No diagnostic specificity was established.

Lung segmentation Dice coefficient

0.91 coefficient

  • EndpointAutomatic lung segmentation agreement
  • Population342 MRI images; image-level test set
  • Tested versionLungMaps VA10A

LungMaps VA10A nonclinical segmentation verification

  • DesignNonclinical image-level segmentation verification
  • PopulationMRI images from participants aged 6-85 years across 0.55T, 1.5T, and 3T systems
  • Scopeexact submission
  • Tested versionLungMaps VA10A
  • Samplen=342
  • IndependenceIndependence not established

K253690

No clinical tests were conducted for the submitted device according to the FDA summary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: One or more 2D MRI time series for lung analysis.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA 510(k) K253690: LungMaps VA10A

  2. Routing

    Source context, not route validation: The FDA summary identifies an OpenApp deployment hosted on syngo.via.

    Scope: Exact FDA submission. Current syngo versions and local implementation requirements need confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · FDA 510(k) K253690: LungMaps VA10A

  3. AI processing

    Source context, not route validation: OpenApp hosted on syngo.via

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · FDA 510(k) K253690: LungMaps VA10A

  4. Returned objects

    Source context, not route validation: Lung ventilation/perfusion maps and statistical evaluation.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA 510(k) K253690: LungMaps VA10A

  5. Viewer/worklist/report

    Unresolved route: Lung ventilation/perfusion maps and statistical evaluation.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA 510(k) K253690: LungMaps VA10A

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
OpenApp hosted on syngo.via
  • Exact FDA submission
  • Checked 2026-09-05
Integration
The FDA summary identifies an OpenApp deployment hosted on syngo.via.
  • Exact FDA submission
  • Checked 2026-09-05

Current syngo versions and local implementation requirements need confirmation.

Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.

Monitoring
Siemens Healthineers' cybersecurity page states that its Cybersecurity Management Service maintains a product security inventory of over 1,000 product versions and over 21,000 monitored software components, with security whitepapers, SBOMs and vulnerability assessments delivered via teamplay Fleet, and that it operates incident and vulnerability management.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.

Vendor family environment

The vendor describes lung map and parameter-report workflows with syngo MR and syngo.via requirements.

product family · checked 2026-09-05

That page states the offering is under development and not commercially available; it does not negate FDA clearance or establish U.S. commercial availability.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253690
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-06-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
25Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored PubMed or ClinicalTrials candidates. Native-submission recall candidate snapshot was zero. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision material, vendor product page, literature index, trial registry, fda device recall, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-06 - Exact FDA submission

    No scoped public price or procurement award was reviewed.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Siemens LungMaps MRI reimbursement"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-06 - Exact FDA submission

    Current training and support terms were not established.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K253690: LungMaps VA10A

    U.S. Food and Drug Administration - Published 2026-06-15 - Accessed 2026-09-19

    Scope: identity, clinicalUse, modality, anatomy, input, output, limitations, integration, deployment, evidenceSummary, evidenceMetrics, purpose, intendedUsers

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. LungMaps model card (K253690)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. LungMaps

    Siemens Healthineers - Accessed 2026-09-05

    Scope: productFamilyWorkflow, implementationCapabilities

  8. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K253690 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260113

uMR Astra

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uMR Astra is a diagnostic MR system for cross-sectional and spectroscopic imaging of the labeled head, body, and extremities.

Modality
MRI
Anatomy
Head; body; and extremities
Decision
2026-05-22
FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

Authorized purpose: S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and anatomy scope.

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K253775

SwiftMR

Airs Medical, Inc.

Authorized purpose: MRI image enhancement through noise reduction and sharpening; clinicians retain responsibility for final patient management decisions.

Modality
MRI
Anatomy
Whole Body
Decision
2026-03-26

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history